Journal of Antivirals & Antiretrovirals
Open Access

Gene Therapy using Viral Vectors and Antiviral Sequences

Mangi Torn^{* *}Correspondence: Mangi Torn, Department of Life Sciences, Monash University, Victoria, Australia, Email:

Author info »

Description

In order to introduce genetic material into cells, molecular scientists frequently utilise viral vectors. This procedure might be carried out inside a living thing or in a culture of cells. In order to effectively transfer their genomes into the cells they infect, viruses have developed unique molecular pathways. Viral vectors have undergone testing for use in medicine; these include Retroviruses (RV), Adenoviruses (AV), Adeno-Associated Viruses (AAV), Lentiviruses (LV), and Herpes Simplex Viruses (HSV). Cell tracking is a practical method for keeping track of certain cell populations' shape, development, proliferation, migration, interaction, function, and other traits both in vitro and in vivo. The continuous biological processes in living creatures may be seen when the target cells are directly or indirectly labelled using various materials and approaches [1]. Viruses have been utilized as vectors to enable gene transfer because of their special capacity to introduce foreign genes into host cells. Target cells that have been genetically marked by viral vectors are able to express reporter genes with great specificity and efficiency. Cells tagged with diverse genetic reporters mediated by various viral vectors may be seen across spatial and temporal scales using the appropriate imaging methods to serve a variety of functions and answer a variety of queries [2]. To emphasize particular cases of cell monitoring in many scientific domains is the underlying principle of employing viral vectors to monitor cells. Adeno- Associated Virus (AAV)-mediated gene therapy has had difficulty treating several prevalent genetic disorders, including Cystic Fibrosis (CF) and Duchenne Muscular Dystrophy (DMD). However, their transduction effectiveness has been too low to be of any use. Trans-splicing AAV (tsAAV) Vectors increase the capacity of AAV packing. Recently, logical vector design helped us get beyond this obstacle. After local injection in dystrophic muscle, we have demonstrated that two optimized minidystrophin tsAAV vectors can achieve the same transduction efficiency as one AAV vector. To cure conditions like DMD, however, requires a worldwide gene transfer. Specialists created a set of optimized alkaline phosphatase tsAAV vectors to determine if systemic delivery is possible using tsAAV vectors [3]. They administered newborn mice AAV serotype 9 pseudotyped AP tsAAV intravenously. Six weeks later, researchers noticed high-level transduction in the heart and every skeletal muscle throughout the body, which are the DMD-affected tissues. The principal organ afflicted by CF, the lung, also showed effective transduction. These findings boost the prospect of tsAAV gene therapy for DMD and CF by offering the first proof of wholebody transduction using tsAAV vectors. Vectors producing luciferase from a liver-specific promoter were observed to transfect hepatocytes in all analyzed liver samples. However, compared to hydrodynamic intraportal injection, the vector copy number and luciferase expression were low. Using a nonintegrating naked DNA vector with replication potential, luciferase expression and the number of vector genomes were found to be 10 times greater in pigs.

Conclusion

The HRII application was less effective than intraportal delivery (lower luciferase activity and vector copy numbers), but it was also much less distressing for the piglets. It also offers the possibility of injecting (or reinjecting) vector DNA by endoscopic cholangiopancreatography. Researchers discuss work in delivering transgenes into neurons or muscles for sensorimotor recovery in animal models of SCI or of stroke incorporating human Neurotrophin-3, with the goal of improving recovery after spinal cord damage in people. It further describe current attempts to create AAVs that are administered peripherally and then transported to specific targets both inside and outside the CNS utilizing better capsid tropisms, cell-type-specific promoters, and techniques for regulating the dosage and duration of transgene expression. In conclusion, less invasive injection of AAVs may enhance recovery following SCI in the future with few adverse effects [4].

References

1. Wang Y, Tang Y, Zhao XM, Huang G, Gong JH, Li H, et al. A Multifunctional Non-viral Vector for the Delivery of MTH1-targeted CRISPR/Cas9 System for Non-Small Cell Lung Cancer Therapy. Acta Biomater. 2022.

   [Cross ref][Google Scholar][PubMed]

2. Chan T, Grisch-Chan HM, Schmierer P, Subotic U, Rimann N, Scherer T, et al. Delivery of non-viral naked DNA vectors to liver in small weaned pigs by hydrodynamic retrograde intrabiliary injection. Mol Ther Methods Clin Dev. 2022;24:268-279.

   [Cross ref][Google Scholar][PubMed]

3. Sydney-Smith JD, Spejo AB, Warren PM, Moon LD. Peripherally delivered Adeno-associated viral vectors for spinal cord injury repair. Exp Neurol. 2022;348:113945.

   [Cross ref][Google Scholar][PubMed]

4. Li Y, Yang L, Zhu S, Luo MH, Zeng WB, Zhao F. In vivo cell tracking with viral vector mediated genetic labeling. J Neurosci Methods. 2021;350:109021.

   [Cross ref][Google Scholar][PubMed]